Wednesday, February 4, 2009

Copaxone is Approved for Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis

Feb 4, 2009 - Teva Pharmaceutical Industries Ltd. today announced that the Medicines and Healthcare products Regulatory Agency has approved an expanded label for COPAXONE® (glatiramer acetate injection) to include the treatment of patients with clinical isolated syndrome (CIS) suggestive of multiple sclerosis (MS).

The details can be read here.

No comments: